본문 바로가기
KERD
논문KCI 등재

만성 신장질환에서 운동 반응성 분자들의 잠재적 보호 기전

The Potential Protective Mechanisms of Exercise-Responsive Molecules in Chronic Kidney Disease

장재승
한국운동생리학회|2024.11|운동과학 (Exercise Science)|제33권 제4호|pp. 366-379|DOI 10.15857/ksep.2024.00472

3

조회

0

다운로드

0

인용

0

참고문헌

키워드

마이오카인MyokineChronic kidney disease만성신장질환엑서카인Exerkine

초록

PURPOSE: Chronic kidney disease (CKD) is a major global health issue characterized by a gradual and irreversible decline in renal function. Despite its increasing prevalence, effective therapeutic options remain limited, highlighting the need for novel treatment approaches. This review highlights the importance of exercise as a nonpharmacological intervention by exploring the role of exerciseinduced bioactive molecules in CKD management. METHODS: An extensive literature review was conducted using PubMed, Scopus, Web of Science, and Google Scholar. The search terms included "myokine,” "exerkine,” "chronic kidney disease,” "nephropathy,” "renal function,” "podocyte,” "mesangial cell,” "exercise,” "physical activity,” and other related terms. RESULTS: Exercise-induced molecules, particularly myokines and exerkines, can slow the progression of CKD through protective mechanisms. These molecules reduce oxidative stress via antioxidant defense pathways, regulate immune responses to limit inflammation, and inhibit fibrotic signaling by interacting with TGF-β and other pro-fibrotic factors. Furthermore, they preserve renal function by maintaining podocyte and mesangial cell integrity and modulating autophagy, thereby preventing kidney damage. CONCLUSIONS: This review consolidates the current knowledge on the therapeutic potential and diverse functions of exerciseinduced molecules in CKD,

Abstract

PURPOSE: Chronic kidney disease (CKD) is a major global health issue characterized by a gradual and irreversible decline in renal function. Despite its increasing prevalence, effective therapeutic options remain limited, highlighting the need for novel treatment approaches. This review highlights the importance of exercise as a nonpharmacological intervention by exploring the role of exerciseinduced bioactive molecules in CKD management. METHODS: An extensive literature review was conducted using PubMed, Scopus, Web of Science, and Google Scholar. The search terms included "myokine,” "exerkine,” "chronic kidney disease,” "nephropathy,” "renal function,” "podocyte,” "mesangial cell,” "exercise,” "physical activity,” and other related terms. RESULTS: Exercise-induced molecules, particularly myokines and exerkines, can slow the progression of CKD through protective mechanisms. These molecules reduce oxidative stress via antioxidant defense pathways, regulate immune responses to limit inflammation, and inhibit fibrotic signaling by interacting with TGF-β and other pro-fibrotic factors. Furthermore, they preserve renal function by maintaining podocyte and mesangial cell integrity and modulating autophagy, thereby preventing kidney damage. CONCLUSIONS: This review consolidates the current knowledge on the therapeutic potential and diverse functions of exerciseinduced molecules in CKD,

참고문헌 (137)

  1. Collaboration GBDCKD, "Global, regional, and national burden of chronic kidney disease, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 395(10225), pp.709~733 (2020)
  2. Kim DH, "Kidney Health Plan 2033 in Korea : bridging the gap between the present and the future", Kidney Res Clin Pract, 43(1), pp.8~19 (2024)
  3. United States Renal Data System: 2022 USRDS annual data report: epidemiology of kidney disease in the United States, "Health NIo.", National Institute of Diabetes and Digestive and Kidney Diseases, ~ (2020)
  4. MacRae C, "Comorbidity in chronic kidney disease : a large cross-sectional study of prevalence in Scottish primary care", Br J Gen Pract, 71(704), pp.243~249 (2021)
  5. Sarnak MJ, "Cardiovascular disease and chronic renal disease:a new paradigm", Am J Kidney Dis, 35(4), pp.117~131 (2000)
  6. Johnson RJ, "Comprehensive clinical nephrology E-Book" (2014), Elsevier Health Sciences
  7. Mallipattu SK, "The podocyte as a direct target for treatment of glomerular disease?", Am J Physiol Renal Physiol, 311(1), pp.46~51 (2016)
  8. Reiser J, "Podocyte biology and pathogenesis of kidney disease", Annu Rev Med, 64, pp.357~366 (2013)
  9. Eddy AA, "Progression in chronic kidney disease", Adv Chronic Kidney Dis, 12(4), pp.353~365 (2005)
  10. Ruiz S, "Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease", Kidney Int, 83(6), pp.1029~1041 (2013)
  11. Shankland SJ, "The podocyte’s response to injury : role in proteinuria and glomerulosclerosis", Kidney Int, 69(12), pp.2131~2147 (2006)
  12. Baker LA, "Clinical practice guideline exercise and lifestyle in chronic kidney disease", BMC Nephrol, 23(1), pp.75~ (2022)
  13. Hayden CM, "Review of exercise interventions to improve clinical outcomes in nondialysis CKD", Kidney International Reports (2024)[DOI]
  14. Ma Q, "The effect of regular aerobic exercise on renal function in patients with CKD : a systematic review and meta-analysis", Front Physiol, 13, pp.901164~ (2022)
  15. Bishop NC, "Exercise and chronic kidney disease : potential mechanisms underlying the physiological benefits", Nat Rev Nephrol, 19(4), pp.244~256 (2023)
  16. Abreu CC, "Does resistance exercise performed during dialysis modulate Nrf2 and NF-kappaB in patients with chronic kidney disease?", Life Sci, 188, pp.192~197 (2017)
  17. Amaral LSB, "Influence of exercise training on diabetic kidney disease : a brief physiological approach", Exp Biol Med(Maywood), 245(13), pp.1142~1154 (2020)
  18. Yang M, "Myokines : Novel therapeutic targets for diabetic nephropathy", Front Endocrinol(Lausanne), 13, pp.1014581~ (2022)
  19. Chow LS, "Exerkines in health, resilience and disease", Nat Rev Endocrinol, 18(5), pp.273~289 (2022)
  20. Whitham M, "The ever-expanding myokinome : discovery challenges and therapeutic implications", Nat Rev Drug Discov, 15(10), pp.719~729 (2016)
  21. Peng H, "Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys", Nat Commun, 8(1), pp.1493~ (2017)
  22. Pedersen BK, "Beneficial health effects of exercise--the role of IL-6 as a myokine", Trends Pharmacol Sci, 28(4), pp.152~156 (2007)
  23. Febbraio MA, "Muscle-derived interleukin-6 : mechanisms for activation and possible biological roles", FASEB J, 16(11), pp.1335~1347 (2002)
  24. Petersen AM, "The anti-inflammatory effect of exercise", J Appl Physiol(1985), 98(4), pp.1154~1162 (2005)
  25. Hawley JA, "Integrative biology of exercise", Cell, 159(4), pp.738~749 (2014)
  26. Lee JH, "Role of myokines in regulating skeletal muscle mass and function", Front Physiol, 10, pp.42~ (2019)
  27. Fox J, "Effect of an acute exercise bout on immediate post-exercise irisin concentration in adults : a meta-analysis", Scand J Med Sci Sports, 28(1), pp.16~28 (2018)
  28. Cheng Y, "Short-and long-term effects of concurrent aerobic and resistance training on circulating irisin levels in overweight or obese individuals : a systematic review and meta-analysis of randomized controlled trials", PeerJ, 12, pp.e17958~ (2024)
  29. Huh JY, "FNDC5 and irisin in humans: I. predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise", Metabolism, 61(12), pp.1725~1738 (2012)
  30. Zhang Y, "Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38MAP kinase and ERK MAP kinase signaling", Diabetes, 63(2), pp.514~525 (2014)
  31. So WY, "Irisin ameliorates hepatic glucose", lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling, 2016, pp.78, 237~247
  32. Ebert T, "Serum levels of the myokine irisin in relation to metabolic and renal function", Eur J Endocrinol, 170(4), pp.501~506 (2014)
  33. Perakakis N, "Physiology and role of irisin in glucose homeostasis", Nat Rev Endocrinol, 13(6), pp.324~337 (2017)
  34. Formigari GP, "Renal protection induced by physical exercise may be mediated by the irisin", AMPK axis in diabetic nephropathy, 2022, pp.12(1), 9062~
  35. Zhang J, "Involvement of GPX4 in irisin’s protection against ischemia reperfusion-induced acute kidney injury", J Cell Physiol, 236(2), pp.931~945 (2021)
  36. Bataille S, "Mechanisms of myostatin and activin A accumulation in chronic kidney disease", Nephrol Dial Transplant, 37(7), pp.1249~1260 (2022)
  37. Khalafi M, "The effects of resistance training on myostatin and follistatin in adults : a systematic review and meta-analysis", Physiol Behav, 269, pp.114272~ (2023)
  38. Rodriguez J, "Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways", Cell Mol Life Sci, 71(22), pp.4361~4371 (2014)
  39. Cheng TC, "Muscle wasting in chronic kidney disease: mechanism and clinical implications-a narrative Review", Int J Mol Sci, 23(11) (2022)
  40. Hanatani S, "Akt1-mediated fast", glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease, 2014, pp.25(12), 2800~2811
  41. Hennebry A, "Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression", Am J Physiol Cell Physiol, 296(3), pp.C525~34 (2009)
  42. Verzola D, "Emerging role of myostatin and its inhibition in the setting of chronic kidney disease", Kidney Int, 95(3), pp.506~517 (2019)
  43. Zhang L, "Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease", FASEB J, 25(5), pp.1653~1663 (2011)
  44. Dong J, "The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro", adipogenic progenitor cells in chronic kidney disease, 2017, pp.91(1), 119~128
  45. Agapova OA, "Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease", Kidney international, 89(6), pp.1231~1243 (2016)
  46. Perera PY, "The role of interleukin-15 in inflammation and immune responses to infection : implications for its therapeutic use", Microbes Infect, 14(3), pp.247~261 (2012)
  47. Nadeau L, "Interleukin-15 as a myokine : mechanistic insight into its effect on skeletal muscle metabolism", Appl Physiol Nutr Metab, 44(3), pp.229~238 (2019)
  48. Hall G, "Interleukin-15 in kidney disease and therapeutics", Curr Opin Nephrol Hypertens, 33(2), pp.174~180 (2024)
  49. Shinozaki M, "IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis", J Clin Invest, 109(7), pp.951~960 (2002)
  50. Tejman-Yarden N, "Renal cells express a functional interleukin-15 receptor", Nephrol Dial Transplant, 20(3), pp.516~523 (2005)
  51. Giron-Michel J, "Interleukin-15 plays a central role in human kidney physiology and cancer through the gammac signaling pathway", PLoS One, 7(2), pp.e31624~ (2012)
  52. Niasse A, "Protective role of the podocyte IL-15", STAT5 pathway in focal segmental glomerulosclerosis, 2024, pp.9(4), 1093~1106
  53. Devocelle A, "Inhibition of TGF-β1 signaling by IL-15 : a novel role for IL-15 in the control of renal epithelial-mesenchymal transition : IL-15 counteracts TGF-β1-induced EMT in renal fibrosis", International Journal of Cell Biology, 2019(1), pp.9151394~ (2019)
  54. Devocelle A, "IL-15prevents renal fibrosis by inhibiting collagen synthesis: a new pathway in chronic kidney disease?", Int J Mol Sci, 22(21) (2021)
  55. Khalafi M, "Interleukin-15 responses to acute and chronic exercise in adults : a systematic review and meta-analysis", Front Immunol, 14, pp.1288537~ (2023)
  56. Barra NG, "Interleukin-15treatment improves glucose homeostasis and insulin sensitivity in obese mice", Diabetes Obes Metab, 14(2), pp.190~193 (2012)
  57. Ceylan HI, "Exploring the effect of acute and regular physical exercise on circulating brain-derived neurotrophic factor levels in individuals with obesity:a comprehensive systematic review and meta-analysis", Biology (Basel), 13(5) (2024)
  58. Rodriguez-Gutierrez E, "Effectiveness of high-intensity interval training on peripheral brain-derived neurotrophic factor in adults : a systematic review and network meta-analysis", Scand J Med Sci Sports, 34(1), pp.e14496~ (2024)
  59. Matthews VB, "Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase", Diabetologia, 52(7), pp.1409~1418 (2009)
  60. Wood J, "BDNF mimetic alleviates body weight gain in obese mice by enhancing mitochondrial biogenesis in skeletal muscle", Metabolism, 87, pp.113~122 (2018)
  61. Chan WS, "Exercise-induced BDNF promotes PPARdelta-dependent reprogramming of lipid metabolism in skeletal muscle during exercise recovery", Sci Signal, 17(828), pp.2783~ (2024)
  62. Yamamoto M, "Expression of mRNAs for neurotrophic factors(NGF, BDNF, NT-3, and GDNF)and their receptors(p75NGFR, trkA, trkB, and trkC)in the adult human peripheral nervous system and nonneural tissues", Neurochem Res, 21(8), pp.929~938 (1996)
  63. Li M, "BDNF repairs podocyte damage by microRNA-mediated increase of actin polymerization", J Pathol, 235(5), pp.731~744 (2015)
  64. Kurajoh M, "Plasma brain-derived neurotrophic factor concentration is a predictor of chronic kidney disease in patients with cardiovascular risk factors-Hyogo Sleep Cardio-Autonomic Atherosclerosis study", PLoS One, 12(6), pp.e0178686~ (2017)
  65. Hsu CY, "Brain-derived neurotrophic factor reduces long-term mortality in patients with coronary artery disease and chronic kidney disease", Front Cardiovasc Med, 9, pp.881441~ (2022)
  66. Cachofeiro V, "Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease", Kidney Int Suppl, 516(111), pp.4~9 (2008)[DOI]
  67. Afsar B, "Brain-derived neurotrophic factor(BDNF) : a multifaceted marker in chronic kidney disease", Clin Exp Nephrol, 26(12), pp.1149~1159 (2022)
  68. Szuhany KL, "A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor", J Psychiatr Res, 60, pp.56~64 (2015)
  69. Seldin MM, "Myonectin(CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis", J Biol Chem, 287(15), pp.11968~11980 (2012)
  70. Petro JL, "Efficacy of high-intensity interval training versus continuous training on serum myonectin and lipid outcomes in adults with metabolic syndrome : a post-hoc analysis of a clinical trial", PLoS One, 19(7), pp.e0307256~ (2024)
  71. Pourranjbar M, "Effects of aerobic exercises on serum levels of myonectin and insulin resistance in obese and overweight women", J Med Life, 11(4), pp.381~386 (2018)
  72. Bahremand M, "A comparison of CrossFit and concurrent training on myonectin, insulin resistance and physical performance in healthy young women", Arch Physiol Biochem, 129(3), pp.603~609 (2023)
  73. Kamiński M, "Myonectin serum concentration changes after short-term physical activity among young, healthy people", Medical Research Journal, 4(1), pp.41~45 (2019)
  74. Otaka N, "Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury", Circ Res, 123(12), pp.1326~1338 (2018)
  75. Zhang J, "Decreased serum myonectin concentrations in diabetic nephropathy patients", Clin Exp Med, 20(4), pp.601~607 (2020)
  76. Neill T, "Decorin : a guardian from the matrix", Am J Pathol, 181(2), pp.380~387 (2012)
  77. Seidler DG, "The galactosaminoglycan-containing decorin and its impact on diseases", Curr Opin Struct Biol, 22(5), pp.578~582 (2012)
  78. Iozzo RV, "Proteoglycan form and function : A comprehensive nomenclature of proteoglycans", Matrix Biol, 42, pp.11~55 (2015)
  79. Mao X, "TGF-beta1 inhibits the autophagy of podocytes by activating mTORC1 in IgA nephropathy", Exp Cell Res, 385(1), pp.111670~ (2019)
  80. Schaefer L, "Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction", Am J Pathol, 160(3), pp.1181~1191 (2002)
  81. Isaka Y, "Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney", Nat Med, 2(4), pp.418~423 (1996)
  82. Kanzleiter T, "The myokine decorin is regulated by contraction and involved in muscle hypertrophy", Biochem Biophys Res Commun, 450(2), pp.1089~1094 (2014)
  83. El Shafey N, "Inhibition of the myostatin", Smad signaling pathway by short decorin-derived peptides, 2016, pp.341(2), 187~195
  84. Domin R, "Effect of various exercise regimens on selected exercise-induced cytokines in healthy people", Int J Environ Res Public Health, 18(3) (2021)
  85. Zhu J, "Relationships between transforming growth factor-beta1, myostatin, and decorin : implications for skeletal muscle fibrosis", J Biol Chem, 282(35), pp.25852~25863 (2007)
  86. Marshall A, "Mighty is a novel promyogenic factor in skeletal myogenesis", Exp Cell Res, 314(5), pp.1013~1029 (2008)
  87. Safdar A, "The potential of endurance exercise-derived exosomes to treat metabolic diseases", Nat Rev Endocrinol, 12(9), pp.504~517 (2016)
  88. Kim H, "Exercise-induced fibroblast growth factor-21: a systematic review and meta-analysis", Int J Mol Sci, 24(8) (2023)
  89. Qian Z, "Close association between lifestyle and circulating FGF21 levels : a systematic review and meta-analysis", Front Endocrinol(Lausanne), 13, pp.984828~ (2022)
  90. Fisher FM, "Understanding the physiology of FGF21", Annu Rev Physiol, 78, pp.223~241 (2016)
  91. Xu J, "Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice", Diabetes, 58(1), pp.250~259 (2009)
  92. Kharitonenkov A, "FGF-21 as a novel metabolic regulator", J Clin Invest, 115(6), pp.1627~1635 (2005)
  93. Liu JJ, "The role of fibroblast growth factor 21in diabetes and its complications : a review from clinical perspective", Diabetes Res Clin Pract, 108(3), pp.382~389 (2015)
  94. Salgado JV, "FGF21 and chronic kidney disease", Metabolism, 118, pp.154738~ (2021)
  95. Salminen A, "Integrated stress response stimulates FGF21 expression : systemic enhancer of longevity", Cell Signal, 40, pp.10~21 (2017)
  96. Kim HW, "Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db", db mice, 2013, pp.154(9), 3366~3376
  97. Lin S, "Fibroblast growth factor 21 attenuates diabetes-induced renal fibrosis by negatively regulating TGFbeta-p53-Smad2", 3-mediated epithelial-to-mesenchymal transition via activation of AKT, 2020, pp.44(1), 158~172
  98. Li S, "Fibroblast growth factor 21ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway", Biomed Pharmacother, 93, pp.695~704 (2017)
  99. Zhang C, "Attenuation of hyperlipidemia-and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation", PLoS One, 8(12), pp.e82275~ (2013)
  100. Zou Y, "Fibroblast growth factor 21 mitigates lupus nephritis progression via the FGF21", Irgm 1, Int Immunopharmacol, pp.2024, 131[DOI]
  101. Tanimura Y, "Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation", Physiol Rep, 4(12) (2016)
  102. Hansen JS, "Glucagon-to-insulin ratio is pivotal for splanchnic regulation of FGF-21 in humans", Mol Metab, 4(8), pp.551~560 (2015)
  103. Ferrara N, "The biology of VEGF and its receptors", Nat Med, 9(6), pp.669~676 (2003)
  104. Song BX, "The effect of exercise on blood concentrations of angiogenesis markers in older adults : a systematic review and meta-analysis", Neurobiol Aging, 135, pp.15~25 (2024)
  105. Zhao Y, "Eight weeks of resistance training with blood flow restriction improve cardiac function and vascular endothelial function in healthy young Asian males", Int Health, 13(5), pp.471~479 (2021)
  106. Shibuya M, "Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis", BMB Rep, 41(4), pp.278~286 (2008)
  107. Otrock ZK, "Vascular endothelial growth factor family of ligands and receptors : review", Blood Cells Mol Dis, 38(3), pp.258~268 (2007)
  108. Rodriguez-Miguelez P, "Hypoxia-inducible factor-1 modulates the expression of vascular endothelial growth factor and endothelial nitric oxide synthase induced by eccentric exercise", Journal of applied physiology, 118(8), pp.1075~1083 (2015)
  109. Leick L, "PGC-1α mediates exercise-induced skeletal muscle VEGF expression in mice", American Journal of Physiology-Endocrinology and Metabolism, 297(1), pp.92~103 (2009)
  110. Slopack D, "Forkhead BoxO transcription factors restrain exercise-induced angiogenesis", J Physiol, 592(18), pp.4069~4082 (2014)
  111. Miao C, "Pro-and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases", Renal failure, 44(1), pp.881~892 (2022)
  112. Schrijvers BF, "The role of vascular endothelial growth factor(VEGF)in renal pathophysiology", Kidney international, 65(6), pp.2003~2017 (2004)
  113. Tatemoto K, "Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor", Biochem Biophys Res Commun, 251(2), pp.471~476 (1998)
  114. Medhurst AD, "Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin", J Neurochem, 84(5), pp.1162~1172 (2003)
  115. de Oliveira AA, "Apelin pathway in cardiovascular, kidney, and metabolic diseases : therapeutic role of apelin analogs and apelin receptor agonists", Peptides, 147, pp.170697~ (2022)
  116. Vinel C, "The exerkine apelin reverses age-associated sarcopenia", Nat Med, 24(9), pp.1360~1371 (2018)
  117. Izadi MR, "High-intensity interval training lowers blood pressure and improves apelin and NOx plasma levels in older treated hypertensive individuals", J Physiol Biochem, 74(1), pp.47~55 (2018)
  118. Kadoglou NP, "The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with type 2 diabetes", Diabet Med, 30(2), pp.e41~50 (2013)
  119. Fujie S, "Reduction of arterial stiffness by exercise training is associated with increasing plasma apelin level in middle-aged and older adults", PLoS One, 9(4), pp.e93545~ (2014)
  120. Han X, "Apelin : a novel inhibitor of vascular calcification in chronic kidney disease", Atherosclerosis, 244, pp.1~8 (2016)
  121. Chen H, "Apelin protects against acute renal injury by inhibiting TGF-beta1", Biochim Biophys Acta, 1852(7), pp.1278~1287 (2015)
  122. Day RT, "Apelin retards the progression of diabetic nephropathy", Am J Physiol Renal Physiol, 304(6), pp.788~800 (2013)
  123. Phillips DJ, "Follistatin : a multifunctional regulatory protein", Front Neuroendocrinol, 19(4), pp.287~322 (1998)
  124. Zhang L, "The emerging role of follistatin under stresses and its implications in diseases", Gene, 639, pp.111~116 (2018)
  125. Hansen J, "Exercise induces a marked increase in plasma follistatin : evidence that follistatin is a contraction-induced hepatokine", Endocrinology, 152(1), pp.164~171 (2011)
  126. Maeshima A, "Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction", Biomed Res Int, 2014, pp.376191~ (2014)
  127. Mehta N, "Follistatin protects against glomerular mesangial cell apoptosis and oxidative stress to ameliorate chronic kidney disease", Antioxid Redox Signal, 31(8), pp.551~571 (2019)
  128. Han X, "Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle", J Cachexia Sarcopenia Muscle, 10(6), pp.1241~1257 (2019)
  129. Kumar KG, "Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism", Cell Metab, 8(6), pp.468~481 (2008)
  130. Lovren F, "Adropin is a novel regulator of endothelial function", Circulation, 122(11), pp.185~192 (2010)
  131. Altamimi TR, "Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency", Metabolism, 98, pp.37~48 (2019)
  132. Jasaszwili M, "Adropin stimulates proliferation but suppresses differentiation in rat primary brown preadipocytes", Arch Biochem Biophys, 692, pp.108536~ (2020)
  133. Fujie S, "Aerobic exercise restores aging-associated reductions in arterial adropin levels and improves adropin-induced nitric oxide-dependent vasorelaxation", J Am Heart Assoc, 10(10), pp.e020641~ (2021)
  134. Fujie S, "Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults", Am J Physiol Heart Circ Physiol, 309(10), pp.H1642~1647 (2015)
  135. Butler AA, "Adropin and insulin resistance: Integration of endocrine, circadian, and stress signals regulating glucose metabolism. Obesity", Silver Spring, 29(11), pp.1799~1801 (2021)
  136. Es-Haghi A, "The Clinical value of serum adropin level in early detection of diabetic nephropathy", Kidney Blood Press Res, 46(6), pp.734~740 (2021)
  137. Kaur R, "Clinical significance of adropin and afamin in evaluating renal function and cardiovascular health in the presence of CKD-MBD biomarkers in chronic kidney disease", Diagnostics (Basel), 13(19) (2023)

관련 논문AI추천

Meeting Physical Activity Guidelines: Impact on Chronic Kidney Disease Prevalence in Diabetic Individuals김준영, 김치호, 박동혁, 이동훈, 이병완, 이용준, 이용호, 전용관연세대학교의과대학 · Yonsei Medical Journal2025 · 제66권 제8호Association of aerobic and muscle-strengthening physical activity with chronic kidney disease in participants with hypertension최영환, Han Yunmin, Kim Yeon Soo대한고혈압학회 · Clinical Hypertension2024 · 제30권 노화예방을 위한 운동과 마이오카인의 역할김기진, 안나영대한운동학회 · 아시아 운동학 학술지2017 · 제19권 제2호Sarcopenia in chronic kidney disease: from bench to bedside송상헌, Da Woon Kim대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제3호Myokines and interorgan crosstalk: bridging exercise to health promotion and disease preventionHa Junseo, Kim Hyeonwoo, Sung Suchan대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2025 · 제30권 제2호혈액투석 중 운동프로그램이 혈액투석 환자의 체력, 생리·혈액지표 및 삶의 질에 미치는 효과: 체계적 문헌고찰유향숙대한체육학회 · 대한체육학회지2018 · 제16권 제1호

이 간행물의 다른 논문 (12건)

A Journey of Growth: Advancing the Future of Exercise Science박현태, 김지석, 조진경pp. 363-365운동에 의한 장내미생물과 유래 대사산물의 변화가 뇌혈관 건강 및 알츠하이머 질환에 미치는 잠재적 영향홍광석, 심다희, 이준희, 이동현pp. 380-389출산 후 엘리트 선수의 임신 전 훈련으로의 복귀 시점: 체계적 문헌고찰 및 메타분석박영민, 박수현, 홍광석, 조진경, 한태경, 강년주pp. 390-398LDA 알고리즘 동적 토픽 모델링을 적용한 운동과학 연구 동향 분석: 2015년부터 2024년까지를 중심으로조혜수, 이동우, 곽동민, 이형근pp. 399-408Collagen Gene Variants and Anterior Cruciate Ligament Rupture in the Korean Population김광준, 장은욱, 성기훈, 박희정, 이병훈, 박동호pp. 409-414
원문 보기